P. Miller

How to Interpret Surrogate Markers of Efficacy in Osteoporosis

M. Hochberg, C. Rosen, M. McClung, 2005 .

Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study

Jacques P. Brown, R. Altman, E. Siris, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Safety and Efficacy of Risedronate in Patients With Age‐Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials

S. Boonen, C. Roux, I. Barton, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial

C. Benhamou, P. Mesenbrink, M. McClung, 2009, Obstetrics and gynecology.

Maintaining the Trust of Physicians and the Public in the Medical Literature: Report of a Task Force on Scientific Publishing of Clinical Trials

M. Drezner, I. Reid, J. Eisman, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study

M. Hochberg, C. Rosen, M. McClung, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.

D. Felsenberg, G. Armbrecht, S. Papapoulos, 2005, Bone.

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

S. Cummings, C. Christiansen, T. Powles, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

R. Recker, M. McClung, A. Kriegman, 2007, Bone.